人C型凝集素18是慢性乙型肝炎病毒感染患者的潜在生物标志

StephenW

J Biomed Sci. 2018 Jul 28;25(1):59. doi: 10.1186/s12929-018-0460-2.
The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection.
Tsai TY1,2, Peng CY2,3, Yang HI4, Huang YL4, Tao MH5, Yuan SS6, Lai HC2, Hsieh SL7,8,9.
Author information

1
    Ph.D. Program for Translational Medicine, China Medical University and Academia Sinica, Taichung and Taipei, Taiwan.
2
    Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, 2, Yude St., North District, Taichung, 404, Taiwan.
3
    School of Medicine, China Medical University, Taichung, Taiwan.
4
    Genomics Research Center, Academia Sinica, 128, Academia Road, Sec. 2, Nankang District, Taipei, 115, Taiwan.
5
    Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Sec. 2, Nankang District, Taipei, 115, Taiwan.
6
    Institute of Statistical Sciences, Academia Sinica, 128, Academia Road, Sec. 2, Nankang District, Taipei, 115, Taiwan.
7
    Genomics Research Center, Academia Sinica, 128, Academia Road, Sec. 2, Nankang District, Taipei, 115, Taiwan. [email protected].
8
    Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. [email protected].
9
    Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan. [email protected].

Abstract
BACKGROUND:

Hepatitis B virus (HBV) infection is a common disease worldwide and is known to cause liver disease. C-type lectin 18 (CLEC18) is a novel secretory lectin highly expressed in human hepatocytes. Because the liver is the major target of HBV infection, we investigated whether the expression of CLEC18 can be used as a biomarker for HBV infection.
METHODS:

The expression level of CLEC18 in human liver chimeric mice with/without HBV infection was measured by quantitative real time polymerase chain reaction (qPCR) assay. Baseline plasma CLEC18 levels in 271 treatment-naive patients with chronic hepatitis B (CHB) undergoing nucleos(t)ide analogue (NUC) therapy and 35 healthy donors were measured by enzyme-linked immunosorbent assay, and the relationships to other clinical data were analyzed.
RESULTS:

The expression of CLEC18 was down-regulated in the human liver chimeric mice after HBV infection. Plasma CLEC18 levels were lower in the patients with CHB compared to the healthy donors and positively correlated with HBV DNA and HBsAg levels (P <  0.05). Multivariate Cox proportional hazard regression analysis identified a baseline plasma CLEC18 level of 320-2000 pg/mL to be an independent predictor of HBeAg loss (hazard ratio (HR): 2.077, P = 0.0318), seroconversion (HR: 2.041, P = 0.0445) and virological response (HR: 1.850, P = 0.0184) in 101 HBeAg-positive patients with CHB undergoing NUC therapy.
CONCLUSIONS:

Plasma CLEC18 levels were correlated with the stage of HBV infection and could predict HBeAg loss and seroconversion in the patients with CHB undergoing NUC therapy.
KEYWORDS:

C-type lectin 18; HBeAg seroconversion; Hepatitis B virus

PMID:
    30055605
DOI:
    10.1186/s12929-018-0460-2

StephenW

J Biomed Sci。 2018年7月28日; 25（1）：59。 doi：10.1186 / s12929-018-0460-2。
人C型凝集素18是慢性乙型肝炎病毒感染患者的潜在生物标志物。
Tsai TY1,2，Peng CY2,3，Yang HI4，Huang YL4，Tao MH5，Yuan SS6，Lai HC2，Hsieh SL7,8,9。
作者信息

1
    博士中国医科大学和中央研究院，台中和台北的转化医学专业。
2
    中国医科大学附属医院内科，肝脏科，2，台中市北区裕德街404号。
3
    中国医科大学医学院，台湾台中。
4
    中国科学院基因组学研究中心，学术路128号，Sec。 2，台北市南康区，台湾115。
五
    中国科学院生物医学研究所，学术路128号2，台北市南康区，台湾115。
6
    中国科学院统计科学研究所，学术路128号2，台北市南康区，台湾115。
7
    中国科学院基因组学研究中心，学术路128号，Sec。 2，台北市南康区，台湾115。 [email protected]。
8
    台湾台北国立阳明大学临床医学研究所。 [email protected]。
9
    台北市台北退伍军人总医院医学研究室。 [email protected]。

抽象
背景：

乙型肝炎病毒（HBV）感染是世界范围内的常见疾病，已知会引起肝脏疾病。 C型凝集素18（CLEC18）是在人肝细胞中高度表达的新型分泌凝集素。由于肝脏是HBV感染的主要靶点，我们研究了CLEC18的表达是否可以用作HBV感染的生物标志物。
方法：

通过定量实时聚合酶链反应（qPCR）测定法测量具有/不具有HBV感染的人肝嵌合小鼠中CLEC18的表达水平。通过酶联免疫吸附试验测定了271名接受核苷（酸）类似物（NUC）治疗的初治慢性乙型肝炎（CHB）患者和35名健康献血者的基线血浆CLEC18水平，并分析了与其他临床数据的关系。
结果：

在HBV感染后，人肝脏嵌合小鼠中CLEC18的表达下调。与健康供者相比，CHB患者血浆CLEC18水平较低，与HBV DNA和HBsAg水平呈正相关（P <0.05）。多变量Cox比例风险回归分析确定基线血浆CLEC18水平320-2000 pg / mL是HBeAg丢失的独立预测因子（风险比（HR）：2.077，P = 0.0318），血清转换（HR：2.041，P = 0.0445） ）在接受NUC治疗的101例HBeAg阳性患者中，病毒学应答（HR：1.850，P = 0.0184）。
结论：

血浆CLEC18水平与HBV感染阶段相关，可预测接受NUC治疗的CHB患者的HBeAg消失和血清转换。
关键词：

C型凝集素18; HBeAg血清学转换;乙型肝炎病毒

结论：
    30055605
DOI：
    10.1186 / s12929-018-0460-2